Conmed buys Bristol-Myers' Linvatec for $370 million

Conmed is to buy the arthroscopy and surgical instruments of Bristol-Myers Squibb's Zimmer division for $370 million in cash. Conmed will acquire the Linvatec business, assets relating to Linvatec's international business and Hall Surgical. In addition, Bristol-Myers will receive a 10-year warrant to purchase one million Conmed shares at 130% of its 15-day average price.

Conmed is to buy the arthroscopy and surgical instruments of Bristol-Myers Squibb's Zimmer division for $370 million in cash. Conmed will acquire the Linvatec business, assets relating to Linvatec's international business and Hall Surgical. In addition, Bristol-Myers will receive a 10-year warrant to purchase one million Conmed shares at 130% of its 15-day average price.

Bristol-Myers announced its intention to sell the two business areas in the summer (see Clinica No 767, p 11). The...

More from Archive

More from Medtech Insight

Veterinary Heart Health Goes High-Tech: Eko And Boehringer Use AI To Spot Heart Murmurs In Dogs

 
• By 

Eko hopes its new partnership with Boehringer Ingelheim to develop algorithms for accurately detecting heart murmurs in dogs will pave the way for more collaborations with medical and pharmaceutical companies to advance early detection in humans as well as animals.

Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist

 

Experts at the Prix Galien UK Forum discussed the future of mental health innovation, emphasizing the important roles of digital solutions, diagnostic biomarkers and community involvement.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By 

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.